Drug Discovery Today

DECEMBER 4, 2019

Horizon’s HAP1 cell line to be integrated in the HPA Cell Atlas program. Knockout cell models from Horizon chosen based on consistency and reproducibility demonstrated in validation studies. Agreement will expand open access resource, supporting genetic research globally

Protein 40

Protein Genetics Research 40

Drug Discovery World

MARCH 24, 2023

Efti As a first-in-class soluble LAG-3 protein targeting MHC Class II ligands on antigen-presenting cells (APC), efti is positioned to improve clinical outcomes from standard-of-care chemotherapy. Its activation of APCs (e.g., month median overall survival (mOS) improvement, statistically significant mOS improvements between 4.2

Trials 52

Trials Immune Response HR Clinical Development 52

Drug Discovery World

JUNE 12, 2023

The International Society for Cellular Therapy (ISCT) is a global society of clinicians, regulators, technologists, and industry partners with a shared mission to drive the translation of all cell and gene therapies for the benefit of patients worldwide. First, the importance of cell collections. Just give me a bag of cells”, she says.

Gene Therapy 52

Gene Therapy Manufacturing Gene Development 52

pharmaphorum

SEPTEMBER 12, 2020

UK cost-effectiveness watchdog NICE has changed its stance on AstraZeneca’s Tagrisso as a first-line therapy for non-small cell lung cancer (NSCLC) after an improved “commercial arrangement” with the company. The post Price cut wins NICE OK for AZ’s Tagrisso in untreated lung cancer appeared first on.

Sales 90

Sales Drugs Clinical Trials Clinical Trials 90

pharmaphorum

JUNE 16, 2022

MorphoSys’ chief executive Jean-Paul Kress said the deal will allow the biotech to “focus our resources on driving our late- and mid-stage oncology pipeline forward.”

Licensing 104

Licensing Licensing Antibody Sales 104

XTalks

FEBRUARY 27, 2024

Iovance Biotherapeutics’ Amtagvi (lifileucel) won US Food and Drug Administration (FDA) approval last week for the treatment of advanced melanoma, making it the first individualized tumor-infiltrating lymphocyte (TIL) therapy and the first T-cell therapy for a solid tumor to win US regulatory approval.

FDA Approval 52

FDA Approval Manufacturing In-Vivo Trials 52

pharmaphorum

SEPTEMBER 8, 2021

“Because NHS staff and resources are scarce, another national mobilisation would potentially leave us with fewer resources for cancer screenings and the other care provided by doctors and nurses each day,” says the AZ executives. ” The post AZ CEO Soriot urges caution on COVID booster doses appeared first on. .

Vaccination 83

Vaccination Vaccine Immune Response Nurses 83

pharmaphorum

SEPTEMBER 22, 2022

That approval also included first-line use of the drug for eligible patients unsuitable for chemo-immunotherapy, typically carried out with bendamustine plus rituximab or dexamethasone plus rituximab and cyclophosphamide. Second indication coming.

Medicine 98

Medicine Drugs Marketing Production 98

The Pharma Data

DECEMBER 22, 2020

22, 2020 — Tagrisso ( osimertinib ) received approval as an adjuvant treatment for patients with non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, the U.S. More News Resources. TUESDAY, Dec. Food and Drug Administration announced Friday. More Information.

Trials 52

Trials Drugs Research 52

pharmaphorum

AUGUST 9, 2021

The Scottish Medicines Consortium (SMC) has cleared NHS funding for Bavencio (avelumab) as a first-line maintenance therapy for people with advanced urothelial carcinoma (UC) – the most common form of bladder cancer – that has not progressed after initial chemotherapy. Both of those uses have also been backed by NICE.

Medicine 52

Medicine Drugs Marketing 52

Drug Discovery World

MAY 23, 2023

DDW’s Megan Thomas caught up with George White , General Manager, Product Management, Cell & Gene Therapy at Cytiva, to learn more about the company’s insight into the CGT market. Key challenges for cell and gene therapies In order for cell and gene (CGT) therapies to succeed, George White identifies several challenges to overcome.

Gene Therapy 52

Gene Therapy Gene Gene Editing Production 52

pharmaphorum

AUGUST 20, 2020

The new guidance recommends Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine, for adults with diffuse large B-cell lymphoma (DLBCL), in second line when patients cannot have a stem cell transplant. This has swayed NICE, which says it considers Polivy to be a cost-effective use of NHS resources.

Drugs 52

Drugs Clinical Trials Clinical Trials Protein 52

Triage Cancer

NOVEMBER 3, 2020

If there are long lines and you have a physical or mental health condition or disability that makes it difficult for you to stand in line, tell a poll worker. Take your cell phone if you have one. If you are in line when the polls close, stay in line, you have the right to vote. Have Questions or Concerns?

98

98

Drug Discovery World

JANUARY 18, 2024

Cancer immunotherapies, such as bispecific antibodies and CAR-T cell therapy, are rapidly moving into earlier lines of treatment in many tumour types, with these markets anticipated to grow to US$100bn+ (~35% CAGR) by 2030 3. In the US, the American Cancer Society estimates that there will be 24.6 million cases of cancer by 2030 1,2.

In-Vivo 64

In-Vivo Antibody Clinical Trials Clinical Trials 64

Intouch Solutions

OCTOBER 5, 2021

During her treatment, tissue was taken for study without her consent; her cells continue to be used in medical research. As TIME said in 1972, “Such a failure seems almost beyond belief, or human compassion.” Henrietta Lacks was a young mother of five when she died from cervical cancer in 1951.

Development 52

Development Research Marketing 52

pharmaphorum

AUGUST 27, 2021

The draft document covers the use of Darzalex (daratumumab) as an add-on to standard induction treatment with Takeda’s Velcade (bortezomib) plus thalidomide and dexamethasone given to patients prior to a stem cell transplant. It is also considering short-term of use of Darzalex as post-transplant therapy.

Clinical Trials 52

Clinical Trials Clinical Trials Antibody Trials 52

pharmaphorum

OCTOBER 23, 2020

As recently as June, NICE was minded not to back routine NHS of MSD’s Keytruda as a first-line treatment for advanced head and neck cancer , but it has had a partial change of heart on the drug after the company submitted new data. The post NICE changes stance on Keytruda for first-line head and neck cancer appeared first on.

Drugs 64

Drugs Manufacturing Medicine Trials 64

pharmaphorum

JANUARY 8, 2021

NICE has rejected Bristol Myers Squibb’s immunotherapy Opdivo as a second-line treatment for head and neck cancer in first draft guidance, unconvinced by evidence unearthed during a three-year NHS trial period. This releases an immune response, allowing T-cells to interact with the cancer cells and destroy them.

Immune Response 52

Immune Response Clinical Trials Clinical Trials Protein 52

pharmaphorum

NOVEMBER 14, 2022

Investors in TauRx Pharma have exercised warrants worth around $119 million, adding to the biotech’s financial resources as it prepares regulatory filings for tau-targeting Alzheimer’s drug hydromethylthionine mesylate (HMTM) on the back of its recently-reported LUCIDITY trial.

Drugs 52

Drugs Protein Clinical Trials Clinical Trials 52

The Pharma Data

SEPTEMBER 8, 2021

Adds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy. Sanofi plans to fund the transaction with available cash resources. per share in cash.

FDA Approval 52

FDA Approval Medicine Marketing Development 52

Roots Analysis

MAY 3, 2022

According to W Chan Kim, and Renee Mauborgne, four primary hurdles to execute a strategy include cognitive hurdle, resource hurdle, motivational hurdle, and political hurdle. Strategy canvas is a line graph that captures current market landscape and the future possibilities for a company. Our Social Media Platform. Web: [link].

Marketing 52

Marketing Radiology Drugs 52

pharmaphorum

DECEMBER 23, 2020

It also shares commercial rights to BMS’ Idhifa (enasidenib), also for AML, and according to Bloomberg the two drugs should bring in around $244 million in revenues to Agios’ top line this year. Agios hit a setback for Tibsovo in Europe this year however after the EMA rejected the marketing application for the drug. Servier is paying $1.8

Marketing 98

Marketing Drugs Genetics Sales 98

Drug Discovery World

FEBRUARY 14, 2024

Using these advanced technologies, better optimised cell line selection can expedite clone choice, while higher throughput screening and assessment, greater capacity to conduct parallel development, and automated cell line selection, cell culture and downstream development can all have significant impacts on timelines.

Protein 59

Protein Vaccination Vaccine Manufacturing 59

Drug Discovery World

NOVEMBER 16, 2022

Think of a cell culture, where scientists can observe the growth of a cell in the body in an in-vitro setting, and gain an understanding of how they react to different drug compounds. One of these benefits is how cells grown in this type of culture are able to interact with their surroundings, similar to how they would perform in-vivo.

Drugs 97

Drugs In-Vivo In-Vitro Scientist 97

pharmaphorum

MARCH 10, 2022

This trend will continue in the near future with a steady increase in market demand over the coming years, alongside further development in cell and gene therapies,” says Magnelli. Reducing reliance on external resources gives drugmakers greater control over production processes, from cells to a final product.

Production 98

Production Life Science Development Gene Therapy 98

The Pharma Data

SEPTEMBER 10, 2020

Data to be presented include findings from the Phase 3 CROWN study of LORBRENA ® (lorlatinib)* in first-line ALK-positive non-small cell lung cancer (NSCLC), building on Pfizer’s extensive heritage in precision medicine research. Saturday, September 19, 2020. . Solomon B. . . Proffered Paper (Presentation 699O). Cohen E. . .

Production 52

Production Medicine Containment Development 52

The Pharma Data

APRIL 8, 2022

(NYSE: PFE) announced updated results from the Phase 3 CROWN trial, which evaluated LORBRENA® (lorlatinib, available in Europe under the brand name LORVIQUA) versus XALKORI® (crizotinib) in people with previously untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). LORBRENA is approved in the U.S.

Trials 52

Trials HR Development Medicine 52

The Pharma Data

JANUARY 19, 2021

By targeting epigenetic dysregulation, KO-539 removes a critical block on leukemia cell differentiation. “It It allows leukemic blasts to differentiate into mature cells and ultimately die off, leaving the patient with clinical benefits that in some cases include complete remissions,” Wilson explained during the recent J.P.

Protein 52

Protein Trials FDA Approval Development 52

Drug Discovery World

JULY 11, 2023

Up until this point, there has been limited success in the therapeutic space with AI and ML, as the algorithms can be flawed, the databases (although huge by current standards) are still not comprehensive enough, and our existing computing resources are not sufficient to carry out a proper analysis.

Big Data 40

Big Data Development Life Science Drugs 40

The Pharma Data

JANUARY 3, 2021

Based on the strong scientific rationale for telaglenastat in KEAP1/NRF2 mutant non-small cell lung cancer patients, and the safety profile observed in CANTATA, we remain dedicated to advancing our randomized KEAPSAKE trial.”.

Trials 52

Trials Clinical Trials Clinical Trials Containment 52

The Pharma Data

OCTOBER 23, 2020

BD’s multi-test tubes have been CE-approved for trading in the European Economic Area, with expanded clinical application for the identification and enumeration of T-cell subtypes in Covid-19 patients.

Trials 52

Trials Immune Response Clinical Trials Clinical Trials 52

The Pharma Data

MAY 18, 2021

1 Many times, melanoma is caused by damage to the DNA in skin cells. Surgery to remove the cancerous cells is usually the first treatment for stage III melanoma. 4 This means there are changes in a specific gene—the BRAF gene—that has caused cancer cells to form and grow 4. ” Additional Resources.

Nurses 52

Nurses Doctors Doctor Gene 52

Drug Discovery World

SEPTEMBER 14, 2023

Regardless of laboratory size, there can be long-term savings in the amount of manual time and resources needed to perform everyday tasks, as we’ll highlight below. Take a task like doing a cell wash. Valuable scientists may also become bored and look for more exciting work elsewhere that makes better use of their education and skills.

Reagent 111

Reagent Life Science Scientist DNA 111

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) to begin a Phase I clinical trial of hAd5-COVID-19, the company’s novel COVID-19 vaccine candidate that targets both the inner nucleocapsid (N), engineered to activate T cells, and outer spike (S) protein, engineered to activate antibodies against the coronavirus (SARS-CoV-2). i,ii,iii,iv.

Antibody 52

Antibody Vaccination Vaccine Trials 52

The Pharma Data

OCTOBER 18, 2020

Crist will be responsible for building out AVEO’s sales force in anticipation of the potential approval and launch of tivozanib, the Company’s next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), as a treatment for relapsed or refractory renal cell carcinoma. “We About AVEO Pharmaceuticals, Inc.

Sales 52

Sales Clinical Trials Clinical Trials Containment 52

XTalks

FEBRUARY 5, 2024

This article serves as a resource for healthcare professionals, life sciences researchers and industry enthusiasts seeking to stay informed of the latest developments and success stories in oncology therapeutics. Price of Revlimid: A supply of 28 oral 2.5 mg capsules is $24,576.

FDA Approval 101

FDA Approval Drugs Sales Development 101

Drug Discovery World

JUNE 28, 2023

Regardless of laboratory size, there can be long-term savings in the amount of manual time and resources needed to perform everyday tasks, as we’ll highlight below. Take a task like doing a cell wash. Valuable scientists may also become bored and look for more exciting work elsewhere that makes better use of their education and skills.

Reagent 98

Reagent Life Science Scientist DNA 98